Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept Dose-Response Study in SLE
NCT01440231Phase 2Withdrawn
- Sponsor
- EMD Serono
- Start
- Feb 2012
- Primary completion
- Aug 2013
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of atacicept in systemic lupus erythematosus (SLE), sponsored by EMD Serono. Planned start Feb 2012; status: withdrawn.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01440231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440231.